Latest Nicholas J. Vogelzang Stories
THE WOODLANDS, Texas, May 26, 2011 /PRNewswire/ -- McKesson Specialty Care Solutions | US Oncology, a division of McKesson Corporation, announced today that four physicians affiliated with US Oncology Research and the United Network of US Oncology will give oral presentations at the 47(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 3 - 7 at McCormick Place in Chicago.
INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., from June 3 - 7, 2011, including results from PARAMOUNT, a Phase III study of an ALIMTA-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.
This week, the Mesothelioma Applied Research Foundation, the leading organization funding mesothelioma research and providing patient services, announced the election of new Co-Chairs of its Board of Directors. Washington, DC (Vocus/PRWEB) January 26, 2011 The Mesothelioma Applied Research Foundation (Meso Foundation) announced today the election of Axel Hanauske, MD, PhD and Hanne Mintz as Co-Chairs of the Board of Directors of the Mesothelioma Applied Research Foundation.
THE WOODLANDS, Texas, Oct. 12 /PRNewswire/ -- US Oncology, Inc., the nation's leading integrated oncology company, announced today that it has enrolled the 1,000th patient in a Phase I clinical trial through its US Oncology Research Network.
LAS VEGAS, Oct.
THE WOODLANDS, Texas, May 20 /PRNewswire/ -- US Oncology, Inc., the nation's leading integrated oncology company, announced today that two physicians affiliated with US Oncology Research will be honored at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 4 - 8 at McCormick Place in Chicago.
The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results.
Perifosine Continues to Demonstrate Impressive Efficacy, Safety and Tolerability in Metastatic Renal Cell Carcinoma Patients who Progressed after Failing Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor QUEBEC CITY, Sept.
- In medieval musical notation, a sign or neume denoting a shake or trill.